Cargando…

Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study

BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Kiyotake, Yanagida, Noriyuki, Sato, Sakura, Imai, Takanori, Ito, Komei, Kando, Naoyuki, Ikeda, Masanori, Shibata, Rumiko, Murakami, Yoko, Fujisawa, Takao, Nagao, Mizuho, Kawamoto, Norio, Kondo, Naomi, Urisu, Atsuo, Tsuge, Ikuya, Kondo, Yasuto, Sugai, Kazuko, Uchida, Osamu, Urashima, Mitsuyoshi, Taniguchi, Masami, Ebisawa, Motohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527748/
https://www.ncbi.nlm.nih.gov/pubmed/33024480
http://dx.doi.org/10.1016/j.waojou.2020.100463
_version_ 1783589123034972160
author Ogura, Kiyotake
Yanagida, Noriyuki
Sato, Sakura
Imai, Takanori
Ito, Komei
Kando, Naoyuki
Ikeda, Masanori
Shibata, Rumiko
Murakami, Yoko
Fujisawa, Takao
Nagao, Mizuho
Kawamoto, Norio
Kondo, Naomi
Urisu, Atsuo
Tsuge, Ikuya
Kondo, Yasuto
Sugai, Kazuko
Uchida, Osamu
Urashima, Mitsuyoshi
Taniguchi, Masami
Ebisawa, Motohiro
author_facet Ogura, Kiyotake
Yanagida, Noriyuki
Sato, Sakura
Imai, Takanori
Ito, Komei
Kando, Naoyuki
Ikeda, Masanori
Shibata, Rumiko
Murakami, Yoko
Fujisawa, Takao
Nagao, Mizuho
Kawamoto, Norio
Kondo, Naomi
Urisu, Atsuo
Tsuge, Ikuya
Kondo, Yasuto
Sugai, Kazuko
Uchida, Osamu
Urashima, Mitsuyoshi
Taniguchi, Masami
Ebisawa, Motohiro
author_sort Ogura, Kiyotake
collection PubMed
description BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, randomized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51 patients were assigned to the 100%-dose group [hen's egg (HE) = 26, cow's milk (CM) = 13, wheat = 12] and 50 to the 25%-dose group (HE = 25, CM = 13, wheat = 12). Primary outcome was established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by comparing allergic symptoms and immunological changes. RESULTS: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7 vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE), 7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels for egg-white, milk, and wheat decreased at 12 months. CONCLUSIONS: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and wheat. Reducing the maintenance dose for eggs, milk, and wheat may effectively lower the symptoms associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduction of the maintenance dose might be important for milk and wheat, compared to the 25%-dose OIT. TRIAL REGISTRATION: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk, and Wheat-Allergic Children at Outpatient Clinic.
format Online
Article
Text
id pubmed-7527748
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-75277482020-10-05 Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study Ogura, Kiyotake Yanagida, Noriyuki Sato, Sakura Imai, Takanori Ito, Komei Kando, Naoyuki Ikeda, Masanori Shibata, Rumiko Murakami, Yoko Fujisawa, Takao Nagao, Mizuho Kawamoto, Norio Kondo, Naomi Urisu, Atsuo Tsuge, Ikuya Kondo, Yasuto Sugai, Kazuko Uchida, Osamu Urashima, Mitsuyoshi Taniguchi, Masami Ebisawa, Motohiro World Allergy Organ J Article BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, randomized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51 patients were assigned to the 100%-dose group [hen's egg (HE) = 26, cow's milk (CM) = 13, wheat = 12] and 50 to the 25%-dose group (HE = 25, CM = 13, wheat = 12). Primary outcome was established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by comparing allergic symptoms and immunological changes. RESULTS: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7 vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE), 7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels for egg-white, milk, and wheat decreased at 12 months. CONCLUSIONS: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and wheat. Reducing the maintenance dose for eggs, milk, and wheat may effectively lower the symptoms associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduction of the maintenance dose might be important for milk and wheat, compared to the 25%-dose OIT. TRIAL REGISTRATION: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk, and Wheat-Allergic Children at Outpatient Clinic. World Allergy Organization 2020-09-29 /pmc/articles/PMC7527748/ /pubmed/33024480 http://dx.doi.org/10.1016/j.waojou.2020.100463 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ogura, Kiyotake
Yanagida, Noriyuki
Sato, Sakura
Imai, Takanori
Ito, Komei
Kando, Naoyuki
Ikeda, Masanori
Shibata, Rumiko
Murakami, Yoko
Fujisawa, Takao
Nagao, Mizuho
Kawamoto, Norio
Kondo, Naomi
Urisu, Atsuo
Tsuge, Ikuya
Kondo, Yasuto
Sugai, Kazuko
Uchida, Osamu
Urashima, Mitsuyoshi
Taniguchi, Masami
Ebisawa, Motohiro
Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title_full Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title_fullStr Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title_full_unstemmed Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title_short Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
title_sort evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: a multicenter randomized study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527748/
https://www.ncbi.nlm.nih.gov/pubmed/33024480
http://dx.doi.org/10.1016/j.waojou.2020.100463
work_keys_str_mv AT ogurakiyotake evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT yanagidanoriyuki evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT satosakura evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT imaitakanori evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT itokomei evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT kandonaoyuki evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT ikedamasanori evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT shibatarumiko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT murakamiyoko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT fujisawatakao evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT nagaomizuho evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT kawamotonorio evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT kondonaomi evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT urisuatsuo evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT tsugeikuya evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT kondoyasuto evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT sugaikazuko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT uchidaosamu evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT urashimamitsuyoshi evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT taniguchimasami evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy
AT ebisawamotohiro evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy